Systemic adverse events and all-cause mortality following same-session bilateral intravitreal anti-VEGF injections: a systematic review.
Adverse event
Anti-VEGF
Bilateral
Death
Injection
Intravitreal
Mortality
Risk
Same-day
Same-session
Systematic review
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
09 Jan 2024
09 Jan 2024
Historique:
received:
27
06
2023
accepted:
29
12
2023
revised:
29
11
2023
medline:
9
1
2024
pubmed:
9
1
2024
entrez:
9
1
2024
Statut:
aheadofprint
Résumé
To review the risk of systemic adverse events and all-cause mortality following same-day bilateral anti-VEGF injections. Twelve literature databases were searched for studies on same-session bilateral intravitreal anti-VEGF injections. Studies reporting on systemic adverse events and mortality were included. Data extraction was made independently by two authors and discussed afterwards until consensus was reached. Seven studies were included with a total of 13,406 intravitreal anti-VEGF injections (6703 bilateral injections sessions) given to 689 patients. Across all studies, mean age of patients ranged from 55.7 to 82.5 years, and mean follow-up times ranged from 1.3 to 41 months. Six studies reported on systemic adverse events: Two cases of non-fatal cardiac adverse events were reported after 12,964 injections (6482 bilateral injection sessions) in 626 patients. Four studies reported on death: 12 deaths were recorded after 6233 bilateral injection sessions in a total population of 554 subjects. We suggest that the risk of non-fatal systemic adverse events and death after same-session bilateral anti-VEGF injection is reasonably low, but larger studies with follow-ups of several years are needed to quantify the exact risk. Prospectively registered in PROSPERO, registration ID: CRD42023428254, registration date: 20/05/2023.
Identifiants
pubmed: 38194112
doi: 10.1007/s00417-023-06368-8
pii: 10.1007/s00417-023-06368-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bloch SB, Larsen M (2015) Translational public health care perspective: intravitreal treatment of neovascular age-related macular degeneration has revolutionized clinical ophthalmology. Acta Ophthalmol 93:103–104. https://doi.org/10.1111/aos.12680
doi: 10.1111/aos.12680
pubmed: 25688486
Lee AY, Day AC, Egan C, Bailey C, Johnston RL, Tsaloumas MD, Denniston AK, Tufail A (2016) Previous intravitreal therapy is associated with increased risk of posterior capsule rupture during cataract surgery. Ophthalmology 123(6):1252–1256. https://doi.org/10.1016/j.ophtha.2016.02.014
doi: 10.1016/j.ophtha.2016.02.014
pubmed: 26996340
Williams GA. IVT Injections (2014) Health policy implications. Review of ophthalmology. Review of Ophthalmology. https://www.reviewofophthalmology.com/article/ivt-injections-health-policy-implications . Accessed 27 June 2023
Mahajan VB, Elkins KA, Russell SR, Boldt HC, Gehrs KM, Weingeist TA, Stone EM, Abràmoff MD, Liu D, Folk JC (2011) Bilateral intravitreal injection of antivascular endothelial growth factor therapy. Retina 31(1):31–35. https://doi.org/10.1097/IAE.0b013e3181ed8c80
doi: 10.1097/IAE.0b013e3181ed8c80
pubmed: 21187731
Freund KB, Vance SK (2011) Systemic safety of bilateral intravitreal anti-vascular endothelial growth factor injections. Retina 31(1):1–3. https://doi.org/10.1097/IAE.0b013e318203c0ef
doi: 10.1097/IAE.0b013e318203c0ef
pubmed: 21187729
Dalvin LA, Starr MR, AbouChehade JE, Damento GM, Garcia M, Shah SM, Hodge DO, Meissner I, Bakri SJ, Iezzi R (2019) Association of intravitreal anti-vascular endothelial growth factor therapy with risk of stroke, myocardial infarction, and death in patients with exudative age-related macular degeneration. JAMA Ophthalmol 137(5):483–490. https://doi.org/10.1001/jamaophthalmol.2018.6891
doi: 10.1001/jamaophthalmol.2018.6891
pubmed: 30703203
pmcid: 6512306
Lee WA, Shao SC, Liao TC, Lin SJ, Lai CC, Lai EC (2021) Comparative risk of arterial thromboembolic events between aflibercept and ranibizumab in patients with maculopathy: a population-based retrospective cohort study. BioDrugs 35(5):579–588. https://doi.org/10.1007/s40259-021-00497-4
doi: 10.1007/s40259-021-00497-4
pubmed: 34495526
Borkar DS, Obeid A, Su DC, Storey PP, Gao X, Regillo CD, Kaiser RS, Garg SJ, Hsu J (2018) Endophthalmitis rates after bilateral same-day intravitreal anti-vascular endothelial growth factor injections. Am J Ophthalmol 194:1–6. https://doi.org/10.1016/j.ajo.2018.06.022
doi: 10.1016/j.ajo.2018.06.022
pubmed: 29981738
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA E (2022). Cochrane handbook for systematic reviews of interventions version 6.3. https://www.training.cochrane.org/handbook . Accessed 27 June 2023
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2021), The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Accessed 27 June 2023
Davis RP, Schefler AC, Murray TG (2010) Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration. Clin Ophthalmol 4:703–707. https://doi.org/10.2147/opth.s10008
doi: 10.2147/opth.s10008
pubmed: 20689785
pmcid: 2915855
Cimbalas A, Svalbonaite E, Levinaitë G, Asoklis R (2012) Simultaneous and separate time bilateral intravitreal injection for patients with neovascular AMD and poor baseline visual acuity. Acta Ophthalmol 90(e250):1–81. https://doi.org/10.1111/j.1755-3768.2012.02549.x
doi: 10.1111/j.1755-3768.2012.02549.x
Shah M, Amoaku WM (2012) Same-day consecutive bilateral intravitreal injections of ranibizumab for the treatment of bilateral active choroidal neovascularization in age-related macular degeneration. Acta Ophthalmol 90(6):e491–e493. https://doi.org/10.1111/j.1755-3768.2011.02327.x
doi: 10.1111/j.1755-3768.2011.02327.x
pubmed: 22269064
Abu-Yaghi NE, Shokry AN, Abu-Sbeit RH (2014) Bilateral same-session intravitreal injections of anti-vascular endothelial growth factors. Int J Ophthalmol 7(6):1017–1021. https://doi.org/10.3980/j.issn.2222-3959.2014.06.20
doi: 10.3980/j.issn.2222-3959.2014.06.20
pubmed: 25540758
pmcid: 4270969
Okoye O, Okonkwo O, Oderinlo O, Hassan K, Ijasan A (2016) Bilateral concomitant intravitreal anti-vascular endothelial growth factor injection: experience in a Nigerian tertiary private eye care facility. Niger J Clin Pract 19(4):544–548. https://doi.org/10.4103/1119-3077.183313
doi: 10.4103/1119-3077.183313
pubmed: 27251975
Juncal VR, Francisconi CLM, Altomare F, Chow DR, Giavedoni LR, Muni RH, Berger AR, Wong DT (2019) Same-day bilateral intravitreal anti-vascular endothelial growth factor injections: experience of a large Canadian retina center. Ophthalmologica 242(1):1–7. https://doi.org/10.1159/000499115
doi: 10.1159/000499115
pubmed: 30928983
Wang D, Choi KS, Lee SJ (2014) Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab. Korean J Ophthalmol 28(1):32–38. https://doi.org/10.3341/kjo.2014.28.1.32
doi: 10.3341/kjo.2014.28.1.32
pubmed: 24505199
pmcid: 3913980
Acharya NR, Sittivarakul W, Qian Y, Hong KC, Lee SM (2011) Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema. Retina 31(9):1871–1876. https://doi.org/10.1097/IAE.0b013e318213da43
doi: 10.1097/IAE.0b013e318213da43
pubmed: 21716165
Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, Bechrakis NE, Kieselbach GF (2015) Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol 93(2):e154–e159. https://doi.org/10.1111/aos.12604
doi: 10.1111/aos.12604
pubmed: 25488124
Ngo Ntjam N, Thulliez M, Paintaud G, Salvo F, Angoulvant D, Pisella PJ, Bejan-Angoulvant T (2021) Cardiovascular adverse events with intravitreal anti-vascular endothelial growth factor drugs: a systematic review and meta-analysis of randomized clinical trials. JAMA Ophthalmol 139(6):1–11. https://doi.org/10.1001/jamaophthalmol.2021.0640
doi: 10.1001/jamaophthalmol.2021.0640
pubmed: 33856414
pmcid: 8050790
Chen YY, Lai YJ, Yen YF, Chou P (2022) Increased mortality after intravitreal injections of anti-VEGF for neovascular AMD among patients with prior stroke or acute myocardial infarction. Eye (Lond) 36(1):153–159. https://doi.org/10.1038/s41433-021-01416-1
doi: 10.1038/s41433-021-01416-1
pubmed: 33654317
Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Le K, Maia M, Visich JE (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98(12):1636–1641. https://doi.org/10.1136/bjophthalmol-2014-305252
doi: 10.1136/bjophthalmol-2014-305252
pubmed: 25001321